Compare NC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | AURA |
|---|---|---|
| Founded | 1913 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.3M | 333.4M |
| IPO Year | 2006 | 2021 |
| Metric | NC | AURA |
|---|---|---|
| Price | $56.74 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 7.7K | ★ 186.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 186.01 | 9.33 |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $104,778,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.00 | $4.73 |
| 52 Week High | $58.99 | $7.73 |
| Indicator | NC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 58.70 |
| Support Level | $44.66 | $5.81 |
| Resistance Level | $58.74 | $5.96 |
| Average True Range (ATR) | 1.76 | 0.36 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 66.52 | 87.80 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.